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The Journal of Immunology
The Atypical Chemokine Receptor Ackr2 Constrains NK Cell
Migratory Activity and Promotes Metastasis
Christopher A. H. Hansell,1 Alasdair R. Fraser,1 Alan J. Hayes, Marieke Pingen,
Claire L. Burt, Kit Ming Lee, Laura Medina-Ruiz, Demi Brownlie, Megan K. L. Macleod,
Paul Burgoyne, Gillian J. Wilson, Robert J. B. Nibbs, and Gerard J. Graham
Chemokines have been shown to be essential players in a range of cancer contexts. In this study, we demonstrate that mice
deficient in the atypical chemokine receptor Ackr2 display impaired development of metastasis in vivo in both cell line and
spontaneous models. Further analysis reveals that this relates to increased expression of the chemokine receptor CCR2, specif-
ically by KLRG1+ NK cells from the Ackr22/2mice. This leads to increased recruitment of KLRG1+ NK cells to CCL2-expressing
tumors and enhanced tumor killing. Together, these data indicate that Ackr2 limits the expression of CCR2 on NK cells and
restricts their tumoricidal activity. Our data have important implications for our understanding of the roles for chemokines in the
metastatic process and highlight Ackr2 and CCR2 as potentially manipulable therapeutic targets in metastasis. The Journal of
Immunology, 2018, 201: 000–000.
D
issemination of cells from a primary tumor site is es-
sential for the establishment of metastasis, which is re-
sponsible for the majority of cancer-related deaths (1).
However, our limited understanding of the biology of the meta-
static process has severely hampered therapeutic development.
Recently, chemokines and their receptors have emerged as im-
portant players in the metastatic process (2, 3). The chemokine/
receptor axis is pharmacologically manipulable (4) and therefore
represents a potential therapeutic target in the context of metastasis.
Chemokines are biochemically related and characterized by the
presence of variations on a conserved cysteine motif in their mature
sequences. They are named, as CC, CXC, XC, or CX3C, according
to the variant of this motif that they possess (5). Chemokines are
classified as being either inflammatory or homeostatic according
to the immune contexts in which they function (6, 7) and interact
with target cells by binding to cognate 7-transmembrane–spanning
G-protein–coupled receptors (8). Chemokines and their receptors
are essential for regulating the migration of inflammatory and
homeostatic leukocytes in a range of physiological and patholog-
ical contexts. In metastasis, chemokine receptors such as CXCR4,
CCR7, and CCR10 have been implicated in controlling the tissue
tropism of metastasizing cells (3). Furthermore, once metastatic
cells reach an appropriate tissue, there is clear evidence that they
extravasate from the vasculature using a mechanism that relies in
part on prometastatic macrophages (9). The monocytic precursors
for these macrophages express the chemokine receptor CCR2, and
their recruitment to the site of extravasation is dependent on ex-
pression of its cognate ligand CCL2. Therefore, chemokines and
their receptors are important players in metastasis.
Chemokine function in vivo is also regulated by the atypical
chemokine receptors (ACKRs) (10). There are currently four
members of this family: Ackr1 (DARC), Ackr2 (D6), Ackr3
(CXCR7), and Ackr4 (CCRL1) (11), which are characterized by an
atypical signaling response to chemokine binding and an inability to
directly support leukocyte migration. Ackr2 (12) displays promis-
cuous binding of inflammatory CC chemokines, all of which are
ligands for CCRs 1–5. Ackr2 is prominently expressed on lym-
phatic endothelial cells in resting tissues (13) as well as on some
leukocytes (14–16). In addition, within inflamed skin, it is strongly
expressed on epidermal cells (17). Ackr2 acts as a scavenger re-
ceptor for its ligands, internalizing them and targeting them for
intracellular destruction (18, 19). It therefore has an important role
in the resolution of chemokine-driven inflammatory responses in the
tissues in which it is expressed (10). Ackr2 has also been implicated
in the regulation of inflammation-dependent cancer development in
skin (20) and colorectal cancer models (21).
Interestingly, one of the key ligands for Ackr2 is CCL2, which,
as mentioned above, is strongly implicated in metastasis. We have
therefore examined the involvement of Ackr2 in the metastatic
process using a range of metastatic models. In this study, we show
that Ackr22/2 mice display profoundly impaired metastatic de-
velopment in both cell line and spontaneous models of metastasis.
Further analysis demonstrates that this is a consequence of
hyperresponsiveness of KLRG1+ NK cells from Ackr22/2 mice to
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CCL2, which is expressed by the developing metastatic lesions.
This leads to increased recruitment of NK cells from Ackr22/2
mice to the developing lesions and enhanced tumor killing. Our data
highlight a key interaction between Ackr2 and CCR2 in regulating
metastasis and suggest that driving increased CCR2 expression in
NK cells or isolation and expansion of CCR2HI NK cells may
provide an effective antitumor cell therapeutic product in the con-
text of primary tumors with a high risk of metastatic spread.
Materials and Methods
Mice
Animals were cohoused in individual ventilated cages in a barrier facility
proactive in environmental enrichment. Ackr2‐deficient mice (22) were
bred in‐house (C57BL/6 background); wild type (WT) C57BL6/J mice
were from Charles River Research Models and Services. Polyoma middle
T (PyMT) transgenic mice (23) (FVB background) were kindly provided
by Dr. K. Blyth. Ackr2‐deficient mice (FVB background) were crossed
with PyMT mice to yield Ackr22/2 3 PyMT mice. All experimental mice
were sex matched and used between the ages of 6 and 9 wk. Animal work
was carried out with ethical approval from University of Glasgow under
the revised Animal (Scientific Procedures) Act 1986 and the European
Union Directive 2010/63/EU. All experiments were performed in accor-
dance with relevant guidelines and regulations. The numbers of animals
used in each experiment are noted in the relevant figure legends.
Cell culture
B16F10 and Lewis lung carcinoma cells were obtained from European
Collection of Authenticated Cell Cultures and maintained in RPMI 1640
(Life Technologies), 10% FCS, 2 mM L-glutamine (Life Technologies),
100 U/ml penicillin/streptomycin (Sigma-Aldrich). YAC-1 cells were pur-
chased from the American Type Culture Collection and cultured in sus-
pension as above. All cell lines were cultured under sterile conditions at 37˚C
in 5% CO2 and enzymatically dispersed and washed before administration.
NK cell isolation
NKcells were pre-enriched from lung or spleen (as indicated) using theNKCell
Isolation Kit II, mouse (Miltenyi Biotec) as per the manufacturer’s instructions.
TCRb2ve NK1.1+ CD11b+ KLRG1+ NK cells were then purified to $95%
purity using a FACS sorter (BD FACSAria I or III; Becton Dickinson).
Adoptive transfers
In the therapeutic NK transfer experiment at day 0, recipient WT C57BL/6J
mice received 53 105 B16F10 cells i.v. One day posttumor administration,
mice received 2 3 105 WT or Ackr22/2 TCRb2ve NK1.1+ CD11b+
KLRG1+ NK cells i.v. Mice were culled at day 14, and pulmonary met-
astatic deposits were enumerated. In competitive transfer experiments,
B16F10 melanoma cells were labeled with 10 mM CMTPX (Life Tech-
nologies) per the manufacturer’s instructions. A total of 1 3 106 labeled
B16F10 cells were injected i.v. on day 0. On day 2, TCRb2ve NK1.1+
CD11b+ KLRG1+ NK cells were FACS purified from either WT or
Ackr22/2 mice and differentially labeled with CFSE (Life Technologies)
or 5 mM Cell Proliferation Dye eFluor 670 (eBioscience). The mice were
injected i.v. with at least 1.3 3 106 mixture of labeled WT and Ackr22/2
NK cells. Mice were culled 24 h later, and tissues were taken. Lungs were
perfused as described above and inflated using 1% low–melting point agar.
Lungs and spleen were then placed in 1% paraformaldehyde for 24 h and
transferred to 30% sucrose for a further 24 h before freezing in Cryomatrix
(Thermo Fisher Scientific). Frozen sections (8 mm) were cut on a Shandon
Cryotome FSE (Thermo Fisher Scientific), and fluorescent images were
acquired across nine separate tissue sections using a Zeiss Axio Imager M2
epifluorescence microscope with AxioVision software (release 4.8.2 06‐
2010/Zeiss ZEN 2012 Blue edition). The NK ratio observed in the spleen
was used to calculate the “input” ratio. Images taken at random or centered
on tumor cells were used to calculate “random field” versus “tumor” ratios.
Chemotaxis assay
TCRb2ve NK1.1+ CD11b+ KLRG1+ NK cells were resuspended in che-
motaxis buffer (RPMI 1640 and 0.5% BSA). Approximately 5 3 105 cells
were placed in the upper chambers of 24-well transwell plates (3-mm fil-
ters; Corning) above 600 ml of chemotaxis buffer with or without che-
mokine (PeproTech) and incubated at 37˚C and 5% CO2 for 3 h. Migrated
cells were enumerated by FACS using CountBrite beads (Invitrogen) and
converted into the percentage of input for each subset.
NK cell-killing assays
KLRG1+ NK cells were FACS purified from Ackr22/2 and WT spleens
using a BD ARIA III flow sorter to a purity of ∼99%. These were seeded at
a density of 5 3 104 NK cells per well of a 96-well round-bottomed plate
in RPMI 1640 (Life Technologies), 10% FCS, 2 mM L-glutamine (Life
Technologies), and 100 U/ml penicillin/streptomycin (Sigma-Aldrich).
YAC-1 cells were labeled with CFSE (Life Technologies) and cocultured
with NK cells at the indicated ratios in the presence or absence of Protein
Transport Inhibitor Cocktail (Affymetryx eBioscience) per the manufac-
turer’s instructions. After 5 h incubation, cocultures were stained using
specific Abs for intracellular IFN-g (clone XMG1.2; Affymetryx eBio-
science) and the exocytosis marker CD107 (clone 1D4B; BioLegend). NK
cell production of IFN-g and NK cell–induced YAC-1 cell death was
subsequently determined by flow cytometry. Killing of B16F10 cells by
NK cells in vitro was assessed using the same methodology as for YAC-1
cells.
Histology and immunohistochemistry
Lungs and other tissues were fixed in 4% paraformaldehyde overnight
before transfer to 70% ethanol. Tissues were embedded in paraffin wax
using the Shandon Citadel 1000 (Thermo Shandon). Sections (4-mm thick)
were cut using a Shandon Finesse 325 Microtome. Resultant sections were
stained with Giemsa, H&E, or toluidine blue for subsequent analysis. For
the PyMT study, sections from eight representative regions through each of
the lungs were chosen, and all tumors were enumerated in the tissue.
Giemsa stain was sufficient to discriminate the metastatic colonies from
normal lung tissue. For immunohistochemistry, slides were deparaffinized,
rehydrated through alcohols, and stained using specific Abs. To stain for
CCL2, slides were boiled for 30 min in Tris-EDTA after blocking with
20% goat serum (Vector Laboratories). Goat polyclonal anti-mouse CCL2
(M-18; Santa Cruz Biotechnology) was used as the primary Ab, followed
by an anti-goat HRP (Vector Laboratories) secondary Ab. In the case of
Mac-2, Ag retrieval was not required. Slides were blocked using 20% goat
serum (Vector Laboratories), followed by rat anti-mouse Mac-2 Ab (clone
M3/38) (CEDARLANE), goat anti-rat IgG biotin (Vector Laboratories),
and finally ExtrAvidin-Peroxidase labeled streptavidin-biotin reagent
(Sigma-Aldrich).
Flow cytometric analysis
Spleen cells were harvested, and single-cell suspensions were prepared by
mechanical disruption through a 40-mM EASYstrainer (Greiner Bio-One).
RBCs were subsequently lysed by resuspending the cell pellet in 1 ml RBC
lysis buffer (eBioscience) for 1 min before washing in FACS buffer (PBS,
1% FCS, 0.02% sodium azide, 5 mM EDTA). A total of 1–3 3 106 cells
per well of a 96-well round-bottomed plate were incubated with 50 ml of a
5 mg/ml solution of Fc block (BioLegend) for 15 min on ice, washed twice
with FACS buffer, and stained with fluorescently labeled Abs (various
concentrations) and Via-Probe (BD Biosciences) or fixable viability dye
eFluor 506 or 780 (eBioscience) (to exclude dead cells). Bone marrow
samples were flushed from the bone using a syringe with a 26-gauge
needle charged with FACS buffer. Single-cell suspensions were prepared,
and RBC were lysed as per the spleen. For analysis of blood samples, RBC
were lysed using ammonium chloride solution (STEMCELL Technolo-
gies), according to the manufacturer’s instructions, immediately prior to
staining. Lungs were perfused with PBS/2 mM EDTA, and the tissue was
removed and finely minced with scissors before resuspending in digestion
mixture (3.2 mg/ml Dispase [Roche], 0.4 mg/ml Collagenase P [Roche],
and 0.2 mg/ml DNase I [Life Technologies]) and incubating at 37˚C for
40 min before passing through a 40-mM EASYstrainer (Greiner Bio-One).
RBCs were lysed as previously described for the spleen. For intracellular
cytokine staining, isolated cells were incubated for 5 h in RPMI 1640 10%
FCS, 2 mM L-glutamine, 100 U/ml penicillin/streptomycin at 37˚C, 5%
CO2 in the presence of 13 Cell Stimulation Cocktail (plus protein trans-
port inhibitors; eBioscience). Cultured cells were subsequently stained
for surface Ags, as above, and dead cells were excluded using viabil-
ity dye eFluor 506 or 780 (eBioscience). Cells were fixed using IC Fixation
Buffer (eBioscience), permeabilized using Permeabilization Buffer
(eBioscience), and stained for intracellular cytokines. Positive populations
were defined on the basis of size (to exclude doublet populations), viability
(i.e., viability dye negative), and Fluorescence Minus One isotype controls.
Data were analyzed using FlowJo software (Tree Star).
Abs used for flow cytometry
Abs against the following surface markers were used, with clone names in
parentheses: CD107a (ID4B), TCRb (H57597), KLRG1 (2F1/KLRG1),
NK1.1 (PK136), NKp46 (29A1.4), CD11b (M1/70), CD49f (GoH3),
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Ly-6C (HK1.4), and CD11c (N418), all BioLegend Abs; CD45 (30F11),
CD49b (DX5), Granzyme B (NGZB), and F4/80 (BM8), all eBioscience
Abs; SiglecF (E50-2440; BD Biosciences) with a variety of conjugated
fluorochromes; and Streptavidin Qdot605 (Life Technologies); appropriate
isotype controls were purchased from BD Biosciences or eBioscience.
Tumor models
B16F10 metastasis model. Typically, 5 3 105 B16F10 cells (kindly provided
by Dr. D. Greenhalgh, University of Glasgow) were injected i.v., and mice
were culled and organs were harvested at various time points up to a max-
imum of 14 d postinoculation. In experiments allowed to proceed to day 14,
blinded counts of visible melanic surface tumors were taken. In experiments
in which tumor cells were fluorescently labeled, 1 3 106 cells were used to
improve detectability at early time points. CCR2 blockade experiments were
performed using the small molecule inhibitor CCX872-22A versus a
hydroxylpropyl methylcellulose carrier control, both kindly provided by
ChemoCentryx. Mice received a daily dose of 5 mg/kg s.c. for the duration of
the model starting 2 d prior to injection of B16F10 cells. To deplete
monocyte/macrophage lineages, mice were treated with clodronate liposomes
versus a PBS liposome control (Liposoma; https://clodronateliposomes.com/
?v=7516fd43adaa). Mice were treated i.v. every 4 d with 75 ml of a 5 mg/ml
solution of liposomes, starting 2 d prior to the administration of B16F10
cells, receiving their final dose at day 10 post-B16F10 cell administration
before cull at day 14. To deplete NK cells, mice received 200 ml i.p. of a
1 mg/ml solution of NK1.1 Ab (clone PK136) versus IgG2a isotype control
(both eBioscience). Mice were injected with the Ab 2 d prior to B16F10
treatment and then at days 4 and 10 prior to cull at day 14.
PyMT spontaneous metastasis model. In this model, female mice sponta-
neously develop mammary epithelial tumors by ∼90 d of age, and mice
were monitored throughout to assess tumor growth in the mammary tissue
using tissue calipers. Once any single tumor within one of the eight
mammary pads reached more than 10 mm in any axis, the mouse was
culled, and total mammary tumor burden was calculated. Survival, as
reported in Fig. 2, is defined as time to cull. During the period of primary
tumor growth, there is also metastatic colonization of the lungs, and lung
tissue was collected for histological assessment.
Lentiviral production and transduction of J774.2 cells
Lentiviral particles were produced as described previously (24) with some
modifications. In brief, 4 T-150 flasks of HEK293T cells were transfected
with 50 mg of lentiviral vector (containing ACKR2) and the helper plas-
mids PMD2.G and pD8.91(17.5 and 32.5 mg, respectively). Supernatant
containing the lentiviral particles was collected after 48 and 72 h of in-
cubation. Lentiviral particles were concentrated using PEG 8000 (Promega) at
a final concentration 70 g/l. Viral titers were determined by quantitative PCR
(qPCR), using primers 59 long terminal repeat forward (59-TGTGTGCCCG-
TCTGTTGTGT-39) and 59 long terminal repeat reverse (59-GAGTCCTGC-
GTCGAGAGAGC-39).
For the transduction of J774.2 cells, 6 3 104 cells were plated onto each
chamber of a four-chamber slide and cultured overnight in DMEM.
Twenty-four hours later, medium was replaced with 0.5 ml of DMEM
containing the lentiviral particles (multiplicity of infection 50) and poly-
brene (8 mg/ml). Twenty-four hours posttransduction, lentiviral particles
were removed and replaced with fresh DMEM. The expression of ACKR2
and CCR2 was analyzed 48 h posttransduction.
qPCR
RNA was extracted using RNeasy columns with DNase treatment
(Qiagen), and the amount of RNA was quantified on a Nanodrop 1000
Spectrophotometer (Thermo Fisher Scientific). cDNA was synthesized
using AffinityScript Multiple Temperature cDNA Synthesis Kit (Agilent
Technologies). For all qPCRs, a final concentration of 0.2-mM primers was
used for each PCR set up using PerfeCTa SYBR Green FastMix and ROX
qPCR Master Mix (Quanta BioSciences). qPCRs were performed on a
Prism 7900HT Fast Real-Time PCR System (Applied Biosystems) or a
Real-Time PCR system (Applied Biosystems). The thermal cycles for
qPCR of GAPDH and CCR2 were 95˚C (3 min) for one cycle and 95˚C
(3 s) and 60˚C (30 s) for 40 cycles. Relative expression was calculated
using serial dilutions of cDNA standards. Primer sequences designed for
qPCR and for producing cDNA standards were designed using Primer3
software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). The fol-
lowing primers were used: mouse ACKR2, 59-TTCTCCCACTGCTGCTT-
CAC-39 and 59-TGCCATCTCAACATCACAGA-39; mouse CCR2 QPCR,
59-TGTGGGACAGAGGAAGTGG-39 and 59-GGAGGCAGAAAATAGCA-
GCA-39; and mouse CCR2 standards, 59-AGGGGAGAGCAGAAGGCTA-
A-39 and 59-CCCAGGAAGAGGTTGAGAGA-39.
Chemokine uptake assay
Chemokine receptor expression was detected in leukocytes using fluo-
rescently labeled chemokines as described previously (14, 16, 25, 26) and
as shown diagrammatically in Supplemental Fig. 2. Leukocytes (#23 106
per well) were isolated as described above and cultured (37˚C, 60 min) in
50 ml complete medium (+20 mM HEPES [pH 7.4]) containing 25 nM
Alexa Fluor 647–coupled human CCL2 or CCL22 to detect CCR2 or
Ackr2, respectively (Alexa-CCL2 or Alexa-CCL22 [Almac]). Cells cul-
tured in this way internalize Alexa-chemokine via chemokine receptors or
nonspecific mechanisms and become fluorescent. Specific chemokine re-
ceptor function is identified by comparing WT populations with those
derived from receptor knockouts or comparison with cells cultured in the
presence of 6 250 nM unlabeled mouse chemokine competitor (typically
CCL12; PeproTech). Cells were then briefly washed before immuno-
staining. To detect ACKR2 activity in lung stroma, Alexa-CCL22 was
administered either intratracheally or i.v. Intratracheal detection was per-
formed on euthanized mice. The trachea was exposed, and the lungs were
inflated with 1 ml of 25-nM Alexa-CCL22 6 250 nM unlabeled mouse
chemokine competitor (PeproTech). The trachea was tied off with surgical
thread, and the intact inflated lungs and trachea were removed and incu-
bated in a bath of RPMI 1640 (37˚C, 60 min). Following this period, cells
were isolated enzymatically as described above and stained for flow
cytometric analysis. i.v. detection required the injection of 1 mg Alexa-
CCL22 i.v. Mice were euthanized 2 h postinjection, and tissues were
harvested as described above and stained for flow cytometric analysis.
Statistical analysis
The statistical tests used are indicated in the relevant figure legends. In all
instances, statistical tests were carried out using GraphPad Prism software.
All quantitative data are presented as mean 6 SD.
Results
Ackr22/2 mice display impaired pulmonary metastasis
To examine roles for Ackr2 in metastasis, we initially used the
B16F10 melanoma cell line model. These cells are injected i.v. and
give rise to easily identifiable, melanic, pulmonary metastatic foci.
As shown (Fig. 1Ai), although WT mice displayed numerous
pulmonary metastatic deposits, Ackr22/2 mice displayed mark-
edly fewer metastases. Quantification revealed a highly significant
reduction in metastatic deposits in the lungs of Ackr22/2 com-
pared with WT mice (Fig. 1Aii), and this is further supported by
images of whole lungs from B16F10-treated WT (Supplemental
Fig. 1Ai) and Ackr22/2 (Supplemental Fig. 1Aii) mice. These
images demonstrate numerous metastatic deposits throughout the
WT lung section compared with the very small numbers of de-
posits identified in the Ackr22/2 lungs section. Notably, where
metastases did arise in Ackr22/2 mice, they were histologically
indistinguishable from those in WT mice (Fig. 1Aiii).
We next examined metastatic development in response to i.v.
injection of Lewis lung carcinoma cells (27). Again, Ackr22/2
mice displayed impaired pulmonary metastasis development
(Fig. 1Bi) with significantly fewer metastatic deposits compared
with WT mice (Fig. 1Bii). Low-magnification images of lungs
from Lewis lung carcinoma–bearing WT (Supplemental Fig. 1Bi)
and Ackr22/2 (Supplemental Fig. 1Bii) mice revealed extensive
disruption of the normal lung architecture by large tumor deposits
in WT lungs but only small isolated tumor deposits, among oth-
erwise normal lung tissue, in Ackr22/2 lungs. When they devel-
oped, the metastases in Ackr22/2 lungs were histologically
indistinguishable from those in WT lungs (Fig. 1Biii). Thus,
Ackr22/2 mice display impaired pulmonary metastatic develop-
ment in two separate cell line models of metastasis.
Ackr22/2 mice display impaired development of
spontaneous metastasis
To examine roles for Ackr2 in metastasis from a primary tumor, we
crossed Ackr22/2 mice onto the PyMT background (23). These
mice develop a primary mammary carcinoma that metastasizes
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spontaneously to the lung. In this model, the size of the primary
tumor defines time to cull. As shown (Fig. 2A), there was no dif-
ference in time to cull of WT or Ackr22/2 mice on the PyMT
background, and there were no significant differences in size of the
primary tumor burden (Fig. 2B). Importantly, there was a marked
and significant reduction in the number of pulmonary metastatic
deposits in Ackr22/2 compared with WT mice (Fig. 2Ci). Gross
images of whole lungs (Fig. 2Cii) revealed extensive large meta-
static deposits in WT lungs compared with very small numbers of
metastatic deposits in Ackr22/2 lungs. Where metastatic deposits
did develop in Ackr22/2 3 PyMT mice, they were histologically
indistinguishable from those developing in WT/PyMT mice
(Fig. 2Ciii). Thus, Ackr2 also contributes to metastasis develop-
ment in a model of spontaneous pulmonary metastasis.
Ackr2 does not regulate initial tumor seeding into the lung
As Ackr2 dampens inflammatory chemokine function, we reasoned
that the phenotype in Ackr22/2 mice might relate to altered
B16F10 cell migration to inflammatory CC chemokines. However,
qPCR analysis of B16F10 cells failed to detect expression of any
of the receptors that share ligands with Ackr2 [i.e., CCR1, CCR2,
CCR3, CCR4, and CCR5 (10)]. It is therefore unlikely that altered
migration of B16F10 cells to inflammatory CC chemokines ex-
plains the observed phenotype. Indeed, analysis of the numbers of
dye-labeled B16F10 cells in the lungs 72 h after i.v. administration
revealed no significant differences between WT and Ackr22/2
mice (Fig. 3A), further suggesting that pulmonary migration/
seeding of B16F10 cells is not impaired in Ackr22/2 mice.
It remains possible that although similar numbers of B16F10
cells are detectable in WTand Ackr22/2 lungs, there may be fewer
cells entering the lung parenchyma in Ackr22/2 mice. Monocyte/
macrophage recruitment has been implicated in metastatic
cell extravasation into the lung parenchyma (9), and clodronate
liposome administration confirmed their importance for tumor
formation in the B16F10 model (Fig. 3B). As Ackr2 scavenges the
ligands for the major monocyte/macrophage chemokine receptor
CCR2, it may interfere with metastasis development by impairing
monocyte/macrophage recruitment through alteration of local
chemokine gradients. However, no significant differences in
macrophage numbers were detectable between WT and Ackr22/2
lungs (Fig. 3C), suggesting that defective macrophage recruitment
is unlikely to explain impaired metastatic development in Ackr22/2
mice. Thus, Ackr2 appears not to regulate initial homing of meta-
static cells to the lung.
Given the known involvement of CCL2 [a ligand for CCR2 and
Ackr2 (10)] in metastasis, we compared metastasis development in
WT and CCR22/2 mice. In contrast to other models (9), CCR2
deficiency had no significant impact on pulmonary metastasis in
the B16F10 model (Fig. 3D). This suggests that although mac-
rophages are important for metastasis in this model, they appear
not to be fully dependent on CCR2. We also examined effects of a
well-characterized pharmacological blocker of CCR2 (28, 29) on
metastasis development. Again, CCR2 inhibition had no signifi-
cant effect on metastasis development in WT mice, confirming the
lack of requirement for CCR2 in this model. However, CCR2
inhibition significantly reversed the block in metastasis develop-
ment in Ackr22/2 mice (Fig. 3E).
Together, these data suggest that although development of
metastasis in WT mice is CCR2 independent, a CCR2-dependent
population of cells limits metastatic development in Ackr22/2
mice.
Ackr22/2 KLRG1+ NK cells display increased
CCR2 expression
The above data suggest preferential recruitment of CCR2+
tumoricidal cells to Ackr22/2 lungs, implying CCR2+ leukocyte
FIGURE 1. Impaired metastasis development in Ackr22/2 mice. (A) Ackr22/2 mice display impaired B16F10 melanoma cell metastasis to the lungs.
This is apparent on gross examination of the lungs (Ai) and enumeration of metastatic deposits (n = 21) (Aii). Histological analysis revealed no differences
in overall tumor architecture in WT and Ackr22/2 lungs (Aiii). (B) Ackr22/2 mice display impaired Lewis lung carcinoma cell metastasis to the lungs. This
is apparent on gross examination (Bi) and enumeration of metastatic deposits (Bii). Histological analysis revealed no differences in overall tumor archi-
tecture in WTand Ackr22/2 lungs (n$ 15) (Biii). H&E stained, original magnification35. Unpaired t test was used to assess significance in all cases. Each
experiment was carried out at least three times with similar results.
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involvement. Therefore, we examined levels of inflammatory
leukocytes in WT and Ackr22/2 lungs early in the metastatic
process (72 h), at which time point we assumed antimetastatic
mechanisms to be active. In agreement with the data in Fig. 3, no
significant differences were seen in monocyte recruitment, and
total numbers of other myelomonocytic cells were also similar
(Fig. 4A). In addition, no differences were detected in overall
T cell or NK cell numbers (Fig. 4B). To determine whether
there were specific differences in CCR2-expressing populations,
we selectively measured CCR2+ cells within key leukocyte
populations using Alexa-CCL2 as described (14, 16, 25, 26)
and as detailed in the Materials and Methods section and in
Supplemental Fig. 2. Notably, although we detected no differences
in CCR2+ monocytic or dendritic cell numbers between WT and
Ackr22/2 lungs (Fig. 4C), we detected a highly significant in-
crease in the apparent number of CCR2+ KLRG1+ NK cells (but
not CCR2+ KLRG12 NK cells) in Ackr22/2 lungs (Fig. 4D).
Examination of the Alexa-CCL2 mean fluorescence intensity
(MFI) for these cells showed that, on a cell-per-cell basis,
KLRG1+ NK cells from Ackr22/2 mice display higher levels of
CCR2 than equivalent WT cells (Supplemental Fig. 3A), indi-
cating that the data in Fig. 4Di reflect increased CCR2 expression
on KLRG1+ NK cells from Ackr22/2 mice and not increased cell
numbers. In agreement with the data in Fig. 4C, flow cytometric
analysis failed to detect any differences in CCR2 activity between
monocytes from WT and Ackr22/2 mice, confirming selectivity of
this phenotype for KLRG1+ NK cells (Supplemental Fig. 3B).
The above data were collected from lungs 72 h after i.v. ad-
ministration of B16F10 cells. However, we see a similar increase
in CCR2 expression in Ackr22/2 KLRG1+ NK cells in lungs
from mice at day 14 [i.e., at the termination of the metastasis
model (Supplemental Fig. 3Ci)]. We also note, at this time
point, increased numbers of KLRG1+ NK cells in the Ackr2
compared with WT lungs (Supplemental Fig. 3Cii), perhaps
suggesting that the process of tumor killing by NK cells early in
the metastatic process produces an inflammatory environment
that leads to secondary recruitment of CCR2+ NK cells in
Ackr22/2 lungs.
Thus, impaired metastasis development in Ackr22/2 mice in-
volves CCR2-expressing cells, and these mice display increased
CCR2 expression on KLRG1+ NK cells in metastatic lungs.
NK cells in resting Ackr22/2 mice display increased
CCR2 activity
Next, we compared NK cell populations in restingWTand Ackr22/2
lungs. Again, although no significant differences were detected in
total KLRG1+ NK cell numbers (Fig. 5Ai), we detected signifi-
cantly increased CCR2 expression on KLRG1+ NK cells in resting
Ackr22/2 compared with WT lungs, suggesting a basal difference
in NK cell biology in Ackr22/2mice (Fig. 5Aii). Similar significant
differences were also detected in KLRG1+ (but not KLRG12)
NK cells from Ackr22/2 mice in peripheral blood and spleen
(Fig. 5B), suggesting that increased CCR2 activity is common
to KLRG1+ NK cells in Ackr22/2 mice. Increased CCR2 in
FIGURE 2. Impaired development of spontaneous metastases in Ackr22/2 mice. WT PyMT and Ackr22/2 3 PyMT mice display no differences in per-
centage survival measured as time to cull (n $ 26) (A) or size of primary tumor burden in the mammary glands (n $ 27) (B). However, Ackr22/2 3 PyMT
mice develop fewer metastatic deposits. This is apparent on gross examination (Cii) and enumeration of numbers of metastatic deposits (n $ 20) (i). His-
tological analysis revealed no differences in overall tumor architecture in WTand Ackr22/2 lungs (iii). H&E stained, original magnification35. Unpaired t test
was used to assess significance in all cases. This study was carried out twice with similar results.
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KLRG1+ NK cells from Ackr22/2 mice was reflected in signifi-
cantly higher transcript levels (Fig. 5C). In addition, in transwell
migration assays, KLRG1+ NK cells from Ackr22/2 mice dis-
played significantly enhanced sensitivity to CCL2 and increased
overall levels of migration compared with WT cells (Fig. 5D).
Thus, Ackr22/2 mice display systemic and selective upregulation
of CCR2 on KLRG1+ NK cells.
ACKR2 does not regulate CCR2 activity on a
cell-autonomous basis
We initially hypothesized that Ackr2 had a cell-autonomous effect
on KLRG1+ NK cell expression of CCR2. However, qPCR anal-
ysis revealed only very low-level expression of Ackr2 (Fig. 6A)
that was at the threshold of detection. In addition, ligand binding
assays (Fig. 6B) failed to demonstrate significant levels of Ackr2
activity on these cells above the background level detected on
Ackr22/2 KLRG1+ NK cells. To further investigate potential cell-
autonomous effects of Ackr2, we used lentiviruses to overexpress
Ackr2 in CCR2+ cells (Fig. 6C). Given the difficulties of
transfecting/transducing NK cells and the fact that we have not
previously identified cell-specific differences in Ackr2 function,
we performed these experiments in CCR2+ J774.2 cells. Analysis
of these cells by PCR (Fig. 6C) or flow cytometry (Fig. 6D)
demonstrated no impact of Ackr2 on CCR2 levels. Together, these
data suggest that Ackr2 is unlikely to exert a cell-autonomous
effect in KLRG1+ NK cells.
NK cells from Ackr22/2 mice have enhanced
tumor-homing efficiency
As shown (Fig. 7A), and as previously reported (30), Ab-mediated
NK cell depletion dramatically increased tumor development in
WT mice, confirming a nonredundant role for NK cells in limiting
metastasis in the B16F10 model. Further analysis of pulmonary
metastasis development in WT and Ackr22/2 mice treated with
NK cell–depleting Abs revealed that with both genotypes, the
lungs were full of tumor with extensive associated hemorrhage
(Supplemental Fig. 4A). Quantification of the percentage of total
lung area covered by tumor revealed no significant difference
between WT and Ackr22/2 lungs (Supplemental Fig. 4B). These
data therefore support the nonredundant role for NK cells in
restricting metastasis development in both genotypes. We next
directly investigated the impact of enhanced CCR2 responsiveness
of KLRG1+ NK cells from Ackr22/2 mice on antitumor re-
sponses. KLRG1+ NK cells from Ackr22/2 mice displayed cell-
killing activity indistinguishable from that of WT cells using
either the common NK cell target cell line YAC-1 (31) (Fig. 7B)
or, and in agreement with previous reports (32), B16F10 cells
themselves (Supplemental Fig. 4C). Thus, increased ability of
individual KLRG1+ NK cells to mediate tumor killing cannot
account for impaired metastasis development in Ackr22/2 mice.
In addition, there were no significant differences in CCL2 levels in
resting WT and Ackr22/2 lungs (Fig. 7C) that might contribute to
enhanced basal pulmonary trafficking of NK cells from Ackr22/2
FIGURE 3. Metastatic cell seeding to the lung is independent of Ackr2. (A) CellTracker Orange–labeled B16F10 cells were injected in equal numbers into
WT or Ackr22/2 mice. Seventy-two hours later, metastatic cells in lungs were enumerated using flow cytometry. Data represent numbers of recovered dye-
labeled cells per lung (n = 10). (B) Mice received either PBS-containing liposomes or clodronate liposomes to deplete macrophages. B16F10 cells were then
administered, and metastatic development was assessed by counting pulmonary metastatic deposits (n $ 6). (C) Macrophage numbers in resting WT and
Ackr22/2 lungs were assessed using Mac-2 staining of histological sections. Data are presented as mean Mac-2+ cell numbers per visual field (n $ 17).
Unpaired t test was used to assess significance. (D) WT and CCR22/2 mice were injected with B16F10 cells, and pulmonary metastases were assessed at day
14. Data are presented as percentage of the average WT metastasis score. (E) WT or Ackr22/2 mice were administered vehicle (v) or CCR2 blocker (CCX),
after which they received B16F10 cells. CCX (or v) was then administered every second day, and lung metastatic deposits developing were enumerated 14 d
after B16F10 injection (n $ 7). All experiments were performed at least twice with similar results. Unpaired t test was used to assess significance.
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mice. Interestingly, although B16F10 cells grown in vitro do not
express CCL2, immunostaining revealed strong CCL2 expression
by developing B16F10 metastatic deposits and surrounding stroma
(Fig. 7D), indicating that the process of tumor formation induces
CCL2 expression in these cells. These data further suggest that the
strong expression of CCL2 by the tumor deposits might favor
recruitment of CCR2 overexpressing KLRG1+ NK cells from
Ackr22/2 mice to developing metastases. Indeed, analysis of the
relative proximity of dye-labeled, adoptively transferred, KLRG1+
NK cells from WT and Ackr22/2 mice to tumor deposits (Fig. 7E)
indicated that NK cells from Ackr22/2 mice migrated closer to
CCL2-expressing tumors than WT cells. These data suggest that
enhanced NK cell recruitment directly to sites of developing
metastases explains impaired development in Ackr22/2 mice.
Finally, to formally demonstrate enhanced antitumor activity of
KLRG1+ NK cells from Ackr22/2 mice, we adoptively transferred
either KLRG1+ NK cells from WT or Ackr22/2 mice to WT mice
in receipt of B16F10 cells. As shown (Fig. 7Fi, 7Fii), fewer tumors
developed in WT mice receiving the KLRG1+ NK cells from
Ackr22/2 compared with WT mice. Quantification of tumor
numbers per lung revealed that KLRG1+ NK cells from Ackr22/2
mice were significantly better at suppressing tumor development
than WT counterparts (Fig. 7Fiii). These data are also interesting
in that they suggest that the enhanced CCR2 expression and as-
sociated increased recruitment of NK cells from Ackr22/2 mice to
the metastatic sites (Fig. 7E) is not diminished upon transfer to
WT mice and is thus presumably stable. Thus, in comparison with
WT KLRG1+ NK cells, KLRG1+ NK cells from Ackr22/2 mice
increase tumor killing through enhanced CCR2 responsiveness
and resulting recruitment in closer proximity to CCL2-expressing
tumor deposits.
Discussion
Chemokines and their receptors are fundamental players in me-
tastasis (2, 3, 9). In addition, it is clear that tumoricidal cells, such
as NK cells, will navigate to sites of tumor development using
chemokines and their receptors, although, to our knowledge, this
axis has not been rigorously studied. In this study, we demonstrate
that Ackr22/2 mice display enhanced protection against pulmo-
nary metastasis development. We further demonstrate that this is
associated with increased CCR2 expression by KLRG1+ NK cells
from Ackr22/2 mice and attendant hyperresponsiveness of these
cells to tumor-expressed CCL2. This results in enhanced NK cell
recruitment to the tumor site and an associated increase in tumor
cell killing. Importantly, and as discussed above, we do not see an
increase in the total number of KLRG1+ NK cells in early-stage
metastatic Ackr22/2 lungs; only increased CCR2 expression and
associated enhanced proximity to the metastatic sites are seen. We
therefore propose that CCR2 is likely to play a specific role in
movement of KLRG1+ NK cells within the lung toward metastatic
deposits and not in their initial recruitment from the circulation.
It is notable that monocytes and other CCR2-expressing cells,
including KLRG12 NK cells, do not display enhanced CCR2
expression in Ackr22/2 mice, arguing for a role for Ackr2 in
regulating CCR2 specifically in KLRG1+ NK cells. The absence
of increased CCR2 expression in the other leukocyte populations
also argues against general transcriptional upregulation of CCR2
in Ackr22/2 cells. At this stage, we are unclear as to the precise
mechanism behind the upregulation of CCR2 in Ackr22/2
KLRG1+ NK cells. However, previous analyses identified CCR2
as marking a discrete subpopulation of murine NK cells (33), and
although we do not detect other phenotypic differences between
FIGURE 4. Ackr22/2 mice display differences in CCR2 expression by NK cells. (A) Numbers of the indicated myelomonocytic cells in WT and Ackr22/2
lungs 72 h after administration of B16F10 cells. (B) Numbers of the indicated lymphoid cell types in WT and Ackr22/2 lungs 72 h after administration of
B16F10 cells (n = 17). (C) Relative percentage of live CD45+ myelomonocytic cell subsets that are positive for CCR2 activity as measured by Alexa-CCL2
binding. Data are shown for WT and Ackr22/2 lungs 72 h after B16F10 cell administration (n = 17). (D) Relative percentage (i) and absolute numbers (ii) of
live CD45+ lymphocyte subsets that are positive for CCR2 activity as measured above. Data are shown for WT and Ackr22/2 lungs 72 h after B16F10 cell
administration (n = 17). All experiments were performed at least twice with similar results. Statistical test used in (B) and (C) was one-way ANOVA with
Bonferonni posttest. DC, dendritic cell; Eos, eosinophil; Monos, monocytes; Nɸ, neutrophils.
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WTand Ackr22/2 KLRG1+ NK cells, our current hypothesis is that
the elevated CCR2 expression is an indication of a subtle varia-
tion in NK cell maturation in Ackr22/2 mice. This suggestion is
supported by recent data indicating elevated CCR2 expression in
NK cells with an altered maturation profile (34). We note a recent
publication confirming our metastasis observations that suggests
FIGURE 5. Ackr22/2 KLRG1+ NK cells display increased CCR2 activity. (Ai) KLRG1+ NK cell numbers do not differ between WT and Ackr22/2 lungs at
rest (n = 14). Unpaired t test. (Aii) Alexa-CCL2 binding demonstrates increased CCR2 on resting pulmonary Ackr22/2 KLRG1+ NK cells compared with WT.
Ackr2 specificity of binding was confirmed by competition with excess CCL12 (n = 3). (B) KLRG1+ but not KLRG12 NK cells from blood (Bi) and spleen (Bii)
display increased CCR2-specific binding of Alexa-CCL2. This experiment was performed three times with similar results. (C) Ackr22/2 KLRG1+ NK cells
express higher CCR2 transcript levels than equivalent WT cells (n$ 5). Unpaired t test. Data are presented as relative units of expression.(D) Ackr22/2KLRG1+
NK cells are more responsive to CCL2 in transwell migration assays than WT counterparts. Migration is measured as percentage of input population migrating
toward the indicated CCL2 concentrations (n $ 3). All experiments were performed at least twice with similar results. *p , 0.05, **p , 0.01, ***p , 0.001.
FIGURE 6. ACKR2 does not directly regulate
CCR2 expression. ACKR2 has no cell-autonomous
impact on CCR2 expression levels or binding of CCL2.
(A) qPCR analysis of CCR2 and Ackr2 expression in
NK cells from WT and Ackr22/2 mice. Data are
expressed as relative units normalized to the house-
keeping GAPDH. Data were analyzed using Student t
test. (B) Graph representing Ackr2 expression in
KLRG1+ splenic NK cells expressed as a percentage of
the average WT MFI. Data represent MFI from flow
cytometric assessment of Alexa-CCL22 internaliza-
tion. (n = 9 combined from three independent experi-
ments), t test. (C) Graph displaying relative expression
of indicated genes (ACKR2 and CCR2) as determined
by qPCR in the J774.2 cell line before (ACKR22) and
after (ACKR2+) ACKR2 lentiviral transduction (n = 4
combined from two individual experiments). (D)
Representative flow cytometric histogram of CCR2
surface staining of J774.2 before (gray) and after
(dashed line) ACKR2 lentiviral transduction relative
to isotype control (solid line). Data are presented as
mean 6 SEM.
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that deletion of expression of Ackr2 in hematopoietic progenitor
cells results in CCR2 upregulation in a variety of mature myeloid
cells (35). However, Ackr2 expression is not reported in hemato-
poietic progenitor cells in either the ImmGen (ccbp2 gene desig-
nation in www.immgen.org) or Gene Expression Commons (Ackr2
gene designation in https://gexc.riken.jp) databases, and using
sensitive PCR-based approaches, we have also been unable to detect
Ackr2 in hematopoietic progenitor cells. We therefore do not be-
lieve that this is a plausible explanation for the phenotype reported
and, as noted above, favor a model in which CCR2 elevation is
explained by a subtle but specific alteration in NK cell maturation.
Our data provide an explanation for previous observations re-
garding the association of CCL2 and other chemokines with
metastasis. For example, high serum CCL2 is associated with
increased metastasis and poor overall survival in nasopharyngeal
carcinoma (36). We suggest that this may relate to systemic
downregulation of CCR2 on circulating tumoricidal leukocytes
such as NK cells. Furthermore, deletion of CCL2 or CCL3 in mice
is associated with decreased NK cell (and other leukocyte) at-
traction to, and inhibition of, metastatic lesions (37). These results
are in keeping with the findings of the current study.
In contrast, some of our data conflict with previously published
work. For example, our data show that unlike other models (9, 38,
39), CCR2-dependent macrophage accumulation at sites of met-
astatic cell extravasation is not essential for tumor development in
the B16F10 model. Indeed, we routinely see metastasis develop-
ing in this model on a CCR22/2 background. Nevertheless,
Fig. 3B demonstrates a requirement for macrophages, suggesting
alternative chemokine receptor involvement in prometastatic
macrophage recruitment. Importantly, without this independence
from CCR2-dependent macrophage involvement in metastatic cell
extravasation, we would have been unable to determine the
distinct roles for CCR2 in NK cell–mediated antitumor responses.
Our data, therefore, highlight an additional level of complexity in
the involvement of CCR2 (and potentially other inflammatory
chemokine receptors) in regulating metastasis development.
Our study also highlights novel therapeutic options. Although, as
shown in Fig. 6, Ackr2 does not appear to regulate NK cell CCR2
expression on a cell-autonomous basis, it is clearly involved in
determining CCR2 expression through, for example, subtle alter-
ation of NK cell maturation. If this altered maturation could
be recapitulated by therapeutic systemic impairment of Ackr2
FIGURE 7. NK cells from Ackr22/2 mice have enhanced tumor-homing efficiency. (A) Ab-based NK cell depletion (WT mice) enhances metastasis. (Ai)
Isotype, (Aii) NK cell–depleting Ab (10 mice per group). (B) WT and Ackr22/2 KLRG1+ NK cells display equivalent target cell–killing ability measured by
(Bi) IFN-g and CD107 expression (n = 4) and (Bii) YAC-1 target cell–killing (n = 4). (C) Resting WT and Ackr22/2 lungs display equivalent CCL2 levels
(ELISA of tissue homogenates) (n = 9). (D) Metastatic colonies display strong CCL2 expression. (Di) Isotype, (Dii) anti-CCL2 Ab. (E) Differentially labeled
WT and Ackr22/2 KLRG1+ NK cells were transferred to WT mice 72 h after labeled B16F10 administration and proximity of WTand Ackr22/2 KLRG1+ NK
cells to metastatic deposits were assessed. Original magnification35. (Ei) Field (original magnification340) stained with DAPI (blue) and showing tumor cell
(red) with neighboring Ackr22/2 KLRG1+ NK cell (green). (Eii) WT/Ackr22/2 cell ratio at input and fields incorporating tumor deposits. Reduced ratio
indicates preferential Ackr22/2 KLRG1+ NK cell presence in the indicated field (n = 6). One-way ANOVA, Tukey posttest. (F) WT mice injected with B16F10
cells, followed by WT or Ackr22/2 KLRG1+ NK cells (isolated from spleens). Lung metastases were visualized (Fi and Fii) and enumerated (Fiii) at day 14
(n $ 14). The control group represents metastasis numbers in WT mice that have not been adoptively transferred with NK cells. All experiments were
performed at least twice with similar results. *p = 0.05, unpaired t test.
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function, then this may lead to increased CCR2 expression by
patient NK cells and enhance their antimetastatic potential. Fur-
thermore, and given that CCL2 expression is a common feature of
tumors (3), our data suggest that enhancing CCR2 expression by
NK cells will increase their migration into tumor sites and en-
hance killing of nascent metastatic deposits.
In summary, we demonstrate profoundly impaired metastasis
development in Ackr22/2 mice and highlight enhanced NK cell
responsiveness to CCR2 as the molecular basis for this. We be-
lieve that our study expands our knowledge of chemokine in-
volvement in metastasis and has clear therapeutic potential.
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